Original Research Article

DEVELOPMENT OF UV SPECTROPHOTOMETRIC METHODS AND VALIDATION FOR ESTIMATION OF SIMVASTATIN IN BULK AND TABLET DOSAGE FORM BY ABSORBANCE MAXIMA AND AREA UNDER THE CURVE METHOD

Vinit Chavhan, Kavya Reddy, Kashmira Ahhirao

Department of Pharmaceutical Chemistry, Smt. Kashibai Navale College of Pharmacy, Sinhgad Technical Campus, Kondhwa-Saswad Road, Kondhwa (Bk), Pune-411018

ABSTRACT

Introduction: To develop two simple UV spectrophotometric methods for simultaneous estimation of Simvastatin (SMV) in bulk and tablet dosage form and validate as per ICH guidelines.

Methods: Method A involved Absorbance maxima method which based on the measurement of absorbance of Simvastatin in methanol at λmax of Simvastatin 238 nm and Method B involved Area under the curve (AUC) method which based on the measurement of AUC in the range of 234-240 nm.

Results: The developed methods were validated for linearity, precision, accuracy, LOD and LOQ as per ICH guidelines. Both the methods were found to be linear within the conc. range of 4-32 µg/ml for Simvastatin.

Conclusion: The present methods were found to be simple, linear, precise, accurate and sensitive and can be used for routine quality control analysis for the estimation of Simvastatin in bulk and tablet dosage form.

Keywords: Simvastatin (SMV), Absorbance ratio method, Area under curve method (AUC) and ICH guidelines.

Corresponding author: Mr. Vinit Chavhan, Department of Pharmaceutical Chemistry, Smt. Kashibai Navale College of Pharmacy, Sinhgad Technical Campus, Kondhwa-Saswad Road, Kondhwa (Bk), Pune-411018 (India). T.: Cont. No. (+91) 7875350171; E.: vinchavhan0512@gmail.com

INTRODUCTION

Simvastatin belongs to a class of drugs called HMG-CoA reductase inhibitors commonly called statins that derived synthetically from fermentation products of Aspergillus terreus. [1] It is chemically known as (1S, 3R, 7S, 8S, 8aR)-8-{2-[(2r, 4r)-4-hydroxy-6-oxotetrahydro-2H-pyran-2yl]-ethyl}-3, 7-dimethyl-1, 2, 3, 7, 8.8a hexahydropthalen-1-yl-2, 2-dimethylbutanoate (Fig. 1). All statins act by inhibiting 3-hydroxy-3-methylglutarylcoenzyme. A HMG-CoA reductase, the rate limiting enzyme of the HMG-CoA reductase pathway, the metabolicpath way responsible for the endogenous production of cholesterol mainly used for the treatment of dyslipidaemia and the prevention of cardiovascular diseases. Simvastatin is prodrug which is converted into its β-hydroxy which inhibits HMG CoA reductase(3-hydroxy-3-methyl glutarylCoenzyme A) enzyme, responsible for catalysing the conversion of HMG CoA to mevalonate a rate limiting step in the synthesis of cholesterol in liver. [2] The drug is officially listed in US pharmacopeia, British pharmacopeia and European pharmacopeia. Simvastatin can be estimated by UV
spectrophotometry [3-10, 18, 19], Derivative Ratio spectrophotometry [11-13], Stability Indicating RP-UPLC [15], Stability Indicating RP-HPLC [14-17], RP-HPLC [19-30], Stability indicating HPTLC [31], HPTLC [32-34] and LC-MS/MS [35] alone or in combination with other drugs. Two official methods utilizing HPLC Gradient methodology are reported in European Pharmacopoeia (EP) [36] United State Pharmacopoeia (USP) [37].

Because of cost-effective and minimal maintenance, UV spectrophotometry is always preferred at small scale industries. Literature survey reveals that so far many UV spectrophotometric methods have been reported for the estimation of Simvastatin in alone or in combination with other drugs. But out of them only few methods included single estimation of Simvastatin. Therefore the main objective of the proposed methods were to develop simple, new and economic UV spectrophotometric methods for the estimation of Simvastatin in bulk and tablet dosage form and validate as per ICH guidelines.

![Figure 1. Chemical structure of Simvastatin](image)

**MATERIALS AND METHODS**

**Chemicals and Reagents**

The pure API sample of Simvastatin was obtained as free gift sample from Gen Pharma Ltd; Pune respectively while solvent such as methanol used were of spectroscopy grade (E. Merck India) and double distilled water used for whole experiment. The marketed combined pharmaceutical dosage form of Simvastatin (10 mg) i.e. Simvas (Micro Labs, India) was purchased from local market.

**Instrumentation**

A Jasco double beam UV–visible spectrophotometer, Model: V-630, with a fixed bandwidth (2nm) and 1-cm quartz cell was used for Spectral and absorbance measurements.

**Preliminary solubility studies of drug**

1 gm of Simvastatin was weighed and solubility was checked in 10 ml water, methanol, 0.1N NaOH and 0.1 N HCl. The drug was found to be freely soluble in methanol and practically poorly soluble in water, 0.1N NaOH and 0.1 HCl. Therefore methanol was selected as diluent and Simvastatin was also found to be stable in methanol for 48 hours in stability studies.

**Preparation of standard stock solutions**

Transfer 2.5 mg of pure Sitagliptin phosphate and Simvastatin in separate 25 ml of volumetric flask containing methanol as diluent and then sonicated for 15 minutes and final
volume made up to mark with same diluent to form 100µg/ml std. stock solution of Simvastatin.

**Preparation of calibration curve**

From above std. stock solution of Simvastatin (100 µg/ml), pippete out aliquots 0.4 to 3.2 ml of Simvastatin and transferred to series of 10 ml volumetric flasks and final volume made up to mark with methanol as diluent to form solutions of 4 to 32µg/ml of Simvastatin. These solutions were then scanned in the range of 200-400 nm against diluent as blank. The absorbance maxima (λmax) were found to be 238 nm for Simvastatin and then calibration curve was plotted as absorbance vs concentration.

**Sample preparation for analysis of Tablet formulation**

Twenty tablets (Simvas) containing 10 mg of Simvastatin weighed, average weight calculated and triturated to fine powder and then weight equivalent 10 mg of Simvastatin transferred to 100 ml of volumetric flask containing proposed diluent, then sonicated for 15 minutes and filtered through Whatman filter paper no. 42 to form 100µg/ml of Simvastatin stock solution and final volume made up to mark with diluent. From this, 1 ml of aliquot transferred in 10 ml of volumetric flask containing diluent to form 10µg/ml of Simvastatin stock solution and scanned in the range of 200-400 nm against methanol as blank at 238 nm and then drug content of solution was calculated by using standard calibration curve.

**Absorbance maxima method**

For the selection of analytical wavelength, standard solution of Simvastatin was scanned in the spectrum mode from 200 nm to 400 nm separately. From the spectra of drug, λmax of SMV, 238 nm was selected for the analysis (Fig. 2). Aliquots of standard stock solution were made and calibration curve was plotted.

![Figure 2. Absorption maxima of Simvastatin](image)

**Area under curve method**

For the determination of Simvastatin using the area under curve (AUC) method, suitable dilutions of the std. stock solutions (100 µg/mL) of simvastatin were prepared in methanol and scanned in the range of 200 - 400 nm. For Area under curve method, the sampling wavelength ranges from 234-240 nm.(Fig. 3) selected for estimation of Simvastatin and area were integrated between these selected wavelength range, which showed linear response with increasing concentration hence the same wavelength range were used for estimation of tablet formulations.
Validation

The present UV spectrophotometric methods were validated for linearity, precision, accuracy, LOD and LOQ as per ICH guidelines [38] for estimation of Simvastatin in bulk and tablet dosage form.

Linearity

From std. stock solutions of Simvastatin (100 µg/ml), pippete out aliquots of 0.4 to 3.2 ml of Simvastatin transferred to series of 10 ml volumetric flasks and final volume made upto mark with methanol as diluent to form solutions of 4 to 32 µg/ml of Simvastatin. These solutions were then scanned in the range of 200-400 nm against diluent as blank at λmax of Simvastatin and then calibration curve was plotted as absorbance vs concentration to check the linear relationship between absorbance and concentration of Simvastatin.

Precision

Precision study expressed by carrying out Repeatability (intraday precision) and interday precision. The intraday (Repeatability) and interday precision study were carried out by estimating corresponding responses three times on the same day and on the three different days for the three different concentration for (8, 12 and 16 µg/ml) for Simvastatin. The results of precision study were reported in terms of % relative standard deviation.

Accuracy

The accuracy of developed method was carried out by calculating the % recovery of Simvastatin by standard addition method at three different levels i.e. 80 %, 100 % and 120 %. Known amount of standard solutions of SMV (9.6, 12 and 14.4 µg/ml) were added to prequantitated sample solutions of 12 µg/ml of SMV).

LOD and LOQ

Limit of detection (LOD) is defined as lowest concentration of analyte that can be detected while limit of quantitation is defined as lowest concentration of analyte that can be quantitated. With suitable precision and linearity, LOD and LOQ can be calculated from the following formulas

\[ \text{LOD} = 3.3 \times \frac{r}{S} \quad \text{and} \quad \text{LOQ} = 10 \times \frac{r}{S} \]
RESULTS AND DISCUSSION

Method development and optimization

The present study describes development and validation of two simple UV spectrophotometric methods for the estimation of Simvastatin in bulk and tablet dosage form using absorbance maxima method and area under the curve method. Solubility studies indicated that a Simvastatin shows better solubility in methanol solution as compared to solubility in distilled water and the $\lambda_{\text{max}}$ of Simvastatin was found to be 238 nm. Because of cost-effective and minimal maintenance, the present UV spectrophotometric methods can be preferred at small scale industries as compared to other reported methods.

Validation

Linearity

Linearity was evaluated by analysis of Std. SMV at Six different concentrations. SMV found to be linear within conc. range of 4-32µg/ml with regression coefficient of 0.9995 by the method A and 0.9992 by method B. The results of regression analysis are summarized in (Table 1). A result shows that within the concentration range mentioned above, there was an excellent correlation between peak area and concentration.

| Simvastatin | Beer’s Range (µg/ml) | Regression equation | Regression coefficient ($r^2$) |
|-------------|-----------------------|---------------------|-------------------------------|
| Method A    | 4-32                  | $y = 0.0293x - 0.0278$ | 0.9995                       |
| Method B    | 4-32                  | $y = 0.0146x + 0.0078$  | 0.9992                       |

Accuracy (Recovery Study)

The accuracy was assessed by the standard addition method of three replicate determinations of three different solutions containing 9.6, 12 and 14.4µg/ml of SMV. The average % recoveries for three different concentrations was found to be 99.56 for method A and 99.71 for method B. SMV using proposed UV spectrophotometric methods. The higher values
indicated that the proposed UV spectrophotometric method was accurate for the determination of SMV in pharmaceutical dosage form. Results of recovery studies are summarized in (Table 4).

**Table 3. Results of Interday Precision Study**

| Simvastatin | Conc. taken (µg/ml) | Conc. found * (µg/ml) | % Amt. found | S.D. | % R.S.D. |
|-------------|---------------------|-----------------------|--------------|------|----------|
| Method A    | 8                   | 7.83                  | 97.85        | 0.360| 0.363    |
|             | 12                  | 11.63                 | 96.91        | 0.417| 0.419    |
|             | 16                  | 15.47                 | 96.68        | 0.202| 0.205    |
| Method B    | 8                   | 7.91                  | 98.87        | 0.387| 0.391    |
|             | 12                  | 11.78                 | 96.91        | 0.404| 0.408    |
|             | 16                  | 15.81                 | 98.91        | 0.534| 0.536    |

*Average of three estimations

**Table 4. Results of Recovery Studies.**

| Drugs       | Conc. of drug taken (µg/ml) | % Recovery * |
|-------------|-----------------------------|--------------|
|             | From Tablet From API        |              |
| Method A    | 12                          | 9.6          | 99.91 |
|             | 12                          | 12           | 99.80 |
|             | 12                          | 14.4         | 98.98 |
| Method B    | 12                          | 9.6          | 99.30 |
|             | 12                          | 12           | 99.83 |
|             | 12                          | 14.4         | 100.02|

*Average of three estimations

**LOD and LOQ**

The limit of detection was found to be 2.09µg/ml and 2.82µg/ml for method A and for method B respectively. The limit of quantification was found to be 6.33µg/ml for method A and 8.56 µg/ml for method B respectively. Low values of LOD and LOQ indicates that the developed method was sensitive for the estimation SMV in bulk and tablet dosage form. Results of LOD and LOQ are summarized in (Table 5).

**Table 5. Results of LOD and LOQ**

| Drugs | LOD (µg/ml) | LOQ (µg/ml) |
|-------|-------------|-------------|
| Method A | 2.09 | 6.33 |
| Method B | 2.82 | 8.56 |

**Assay**

Analysis of sample of marketed tablet containing 10 mg Simvastatin was carried out and the amounts recovered were expressed as a percentage amount of the label claims. The percentage recovery of Simvastatin were 99.48 for method A and 99.69for method B respectively and these values are complying with the assay specifications for active drug Simvastatin in the United States of Pharmacopoeia (90.0–110.0%) which are required to be met by most drug formulations. Results of tablet assay are summarized in (Table 6).
Table 6. Results of tablet Assay

| Simvastatin | Label Claim (mg/tab) | Amount of Drug* Estimated (mg/tab) | % Assay |
|-------------|----------------------|-----------------------------------|---------|
| Method A    | 10 mg                | 99.66                             | 99.48   |
| Method B    | 10 mg                | 9.86                              | 98.69   |

* Average of Six estimations

CONCLUSION

Simple UV spectrophotometric methods have been developed and validated for the determination of Simvastatin in bulk and tablet dosage form. The results of the validation parameters show that the UV spectrophotometric methods were found to be accurate, precise and sensitive. Because of cost-effective and minimal maintenance, the present UV spectrophotometric methods can be preferred at small scale industries and successfully applied and suggested for the quantitative analysis of Simvastatin in pharmaceutical formulations for QC, where economy and time are essential and to assure therapeutic efficacy.

REFERENCES

1. Merck index, Maryadele J.O. Neil Edu. In: 13 Ed, Merck Research Lab NJ, USA. 2001; 868.
2. Bays HE, Moore PB, Drehobl MA et al effectiveness and tolerability of simvastatin in patients with primary hypercholesterolemia pooled analysis of two phase II studies. Cli. Ther 2001; 23 (8), 1209-1230.
3. Arayne M. S., Sultana N., Hussain F., & Ali, S. A. (2007). Validated spectrophotometric method for quantitative determination of Simvastatin in pharmaceutical formulations and human serum. Journal of Analytical Chemistry, 62(6), 536-541.
4. Jain N., Jain R., Swami H., Pandey S., & Jain D. K. (2009). Spectrophotometric Method for simultaneous estimation of Simvastatin and Ezetimibe in bulk drug and its combined dosage form. Internat. J. Pharmacy Pharm. Sci, 1(1), 170-175.
5. Rajput, S. J., & Raj, H. A. (2007). Simultaneous Spectrophotometric estimation of Ezetimibe and Simvastatin in tablet dosage forms. Indian Journal of Pharmaceutical Sciences, 69(6), 759.
6. Mane, V. B., Babar, S., & Kulkarni, N. (2011). Development of UV Spectrophotometric method for the simultaneous estimation of Simvastatin and Ezetimibe in tablet dosageform by Simultaneous Equation and Absorbance Ratio Method. Development, 3(3), 1459-1466.
7. Balaji, S., & Sunitha, A. (2010). Development and validation of Spectrophotometric method for simultaneous determination of Simvastatin and Ezetimibe in tablet formulations. Pak. J. Pharm. Sci, 23(4), 375-378.
8. Bhatia, N. M., Deshmukh, D. D., Kokil, S. U., & Bhatia, M. S. (2009). Simultaneous Spectrophotometric estimation of Simvastatin and Ezetimibe in tablet formulation. J. Chem, 6(2), 541-544.
9. Palabiyik, I. M., Onur, F., Yardimci, C., & Ozaltin, N. (2008). Simultaneous spectrophotometric determination of Ezetimibe and Simvastatin in pharmaceutical preparations using chemometric techniques. *Química Nova*, 31(5), 1121-1124.

10. Thamake, S. L., Jadhav, S. D., & Pishawikar, S. A. (2009). Development and validation of method for simultaneous estimation of Atorvastatin Calcium and Ramipril from capsule dosage form by first order derivative spectroscopy. *Asian J. Research Chem*, 2(1), 52-53.

11. Moussa, B. A., Mohamed, M. F., & Youssef, N. F. (2010). Derivative Spectrophotometric Method for Simultaneous Determination of Ezetimibe and Simvastatin in combined tablets. *European Journal of Chemistry*, 1(4), 348-351.

12. Joshi, H. V., Patel, J. K., & Kothapalli, L. (2010). Simultaneous Derivative and Multicomponent Spectrophotometric determination of Simvastatin and Ezetimibe in tablets. *Der Pharma Chemica*, 2(2), 152-156.

13. Phaneemdra, D., Venkatesh, V., & Ramarao, N. (2012). Simultaneous estimation of simvastatin and sitagliptin by using different analytical methods. *International Journal of Advances in Pharmaceutical Analysis*, 2(1), 19-23.

14. Abhishek, G. (2012). Development and Validation of Stability Indicating RP-UPLC Method for Simultaneous Determination in Fixed Dose Combination of Ezetimibe and Simvastatin. *Journal of Chromatography & Separation Techniques*.

15. Lakka, N. S., Goswami, N., Balakrishna, P., & Sailaja, V. (2011). Development and validation of a stability-indicating RP-HPLC for the simultaneous determination of Atorvastatin Calcium and Simvastatin in pharmaceutical solid dosage forms. *Int. J Res Pharm Sci*, 2, 608-615.

16. Kavitha K. Y; Geetha G; Hariprasad R; Venkatnarayana R. and Subramanian G. (2012) Development and validation of stbility indicating RP-HPLC method for the simultaneous estimation of Sitagliptin phosphate and Simvastatin. *International research journal of pharmacy*, 3(12), 123-127.

17. Chaudhari, B. G., Patel, N. M., & Shah, P. B. (2007). Stability-Indicating Reversed-Phase Liquid Chromatographic Method for simultaneous determination of Simvastatin and Ezetimibe from their combination drug products. *Journal of AOAC International*, 90(5), 1242-1249.

18. Bonde, P., Sharma, S., Kourav, N., & Attar, A. M. (2010). Development and validated UV spectrophotometric and RP-HPLC methods for the estimation of simvastatin and ezetimibe in combined pharmaceutical dosage form. *Inter J Curr Trends Sci Tech*, 1(3), 135.

19. Sharma, S. (2012). Development of UV Spectrophotometry and RP HPLC Method and Its Validation for Simultaneous Estimation of Sitagliptin Phosphate and Simvastatin in Marketed Formulation. *International Journal of Pharmaceutical & Biological Archive*, 3(3).

20. Jain, N., Jain, R., Swami, H., & Jain, D. K. (2008). RP-HPLC Method for Simultaneous Estimation of Simvastatin and Ezetimibe in Bulk Drug and its Combined Dosage Form. *Asian J. Research Chem*, 1(1), 29-31.

21. Shivshanker, K., Sreekanth, N., Harikrishnan, N., Roosevelt, C., Rao, G. S., & Gunasekaran, V. (2007). Validated simultaneous estimation of simvastatin and
ezetimibe by RP-HPLC in pure and pharmaceutical dosage form. *Asian Journal Of Chemistry, 19*(6), 4303-4308.

22. Samaa, J. R., Kalakuntlab, R. R., Rao, V. S. N., & Reddanna, P. (2010). Simultaneous estimation of Simvastatin and Ezetimibe in pharmaceutical formulations by RP-HPLC method. *J. Pharm. Sci. Res., 2*(2), 82-89.

23. Hefnawy, M., Al-Omar, M., & Julkhuf, S. (2009). Rapid and sensitive simultaneous determination of ezetimibe and simvastatin from their combination drug products by monolithic silica high-performance liquid chromatographic column. *Journal of pharmaceutical and biomedical analysis, 50*(3), 527-534.

24. Madan, J., Thakkar, V., Dwivedi, A. K., & Singh, S. (2007). Ion-pairing RP-HPLC analytical methods for simultaneous estimation of simvastatin and its hydroxyl acid. *J. Sci. Industr. Res, 66*, 371-376.

25. Nagaraju P. (2010). A Validated Reverse Phase HPLC Method for the Simultaneous estimation of Simvastatin and Ezetimibe in Pharmaceutical dosage forms. *Journal of Global Pharma Technology, 2*(4).

26. Kumar DA, Sujan DP, Vijayasree V. & Rao JVLN (2009). Simultaneous determination of Simvastatin and Ezetimibe in tablets by HPLC. *Journal of Chemistry, 6*(2), 541-544.

27. Sultana N, Saeed AM, Naz Shah S, Shafi N. & Naveed S. (2010). Simultaneous determination of prazosin, Atorvastatin, Rosuvastatin and Simvastatin in API, dosage formulations and human serum by RP-HPLC. *Journal of the Chinese Chemical Society, 57*(6), 1286.

28. Rahman MU, Parveen G, Nyola NK, Khan S, Talegaonkar S, Yar MS & Khar RK. (2010). Simultaneous estimation of Simvastatin and Ezetimibe in pharmaceutical tablet dosage forms by RP-HPLC: A review. *Int. J. Pharm. Res. Dev.–Online, 2*(9), 008.

29. Neelima B, Kumar PR., Krishna MM, Bindu VH & Prasad YR. (2008). Simultaneous Estimation of Simvastatin and Ezetimibe by RP-HPLC in pure and pharmaceutical dosage form. *Oriental Journal of Chemistry, 24*(1), 195-200.

30. Ochiai H, Uchiyama N, Imagaki K, Hata S, Kamei T. Determination of simvastatin and its active metabolites in human plasma by column-switching high performance liquid chromatography with fluorescence detection after derivatization with bromo acetyl pyrene. *J Chromatogr Biomed Sci. 1997; 694*(1):211-217.

31. Dixit RP, Barhate CR. & Nagarsenker MS. (2008). Stability-indicating HPTLC method for simultaneous determination of Ezetimibe and Simvastatin, *Chromatographia, 67*(1-2), 101-107.

32. Chaudhari BG, Patel, N. M., & Shah, P. B. (2007). Determination of Simvastatin, Pravastatin sodium and Rosuvastatin calcium in tablet dosage forms by HPTLC. *Indian journal of pharmaceutical sciences, 69*(1), 130.

33. Dhaneshwar, S. S., Deshpande, P., Patil, M., Vadnerkar, G., & Dhaneshwar, S. R. (2008). Development and validation of a method for simultaneous densitometric analysis of Simvastatin and Ezetimibe as the bulk drugs and in the tablet dosage form. *Acta Chromatographica, 20*(1), 71-79.
34. Rathinaraj S. (2010). Development and Validation of A HPTLC Method for the Estimation of Simvastatin and Ezetimibe. *International Journal of Pharmaceutical & Biological Archive*, 1(4).

35. Barrett, B., Huclova, J., Bořek-Dohalský, V., Němec, B., & Jelinek, I. (2006). Validated HPLC–MS/MS method for simultaneous determination of simvastatin and simvastatin hydroxy acid in human plasma. *Journal of pharmaceutical and biomedical analysis*, 41(2), 517-526.

36. Europian Pharmacopoeia. Council of Europe, Strasbourg Cedex. 2002, 4th Edition.

37. United States Pharmacopoeia, USP30-NF25, Pharmacopeial Forum. 2002, 32(1), 3179.

38. ICH, Validation of Analytical Procedures: Methodology Q2 (R1), International Conference on Harmonization, IFPMA, Geneva, 1996.